These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1745337)

  • 1. [Comparison of calcium acetate and calcium carbonate for the control of predialysis hyperphosphatemia].
    Djerad M; Morinière P; Westeel PF; el Esper N; Boitte F; Morsli R; Schenouda M; Compagnon M; Achard JM; Fournier A
    Nephrologie; 1991; 12(4):193-7. PubMed ID: 1745337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia.
    Morinière P; Djerad M; Boudailliez B; el Esper N; Boitte F; Westeel PF; Compagnon M; Brazier M; Achard JM; Fournier A
    Nephron; 1992; 60(1):6-11. PubMed ID: 1738415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium acetate used as phosphate binding treatment in uremic hyperphosphatemia.
    Wikström B; Danielson BG; Fellström B
    Adv Perit Dial; 1991; 7():221-4. PubMed ID: 1680430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of the time of administration of calcium carbonate (before or during mealtime) in the control of hyperphosphatemia in patients on maintenance hemodialysis].
    Séchet A; Abighanem O; Said S; Rasombololona M; Morinière P; Brazier M; Fournier A
    Nephrologie; 1999; 20(4):209-12. PubMed ID: 10480153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.
    Mactier RA; Van Stone J; Cox A; Van Stone M; Twardowski Z
    Clin Nephrol; 1987 Nov; 28(5):222-6. PubMed ID: 3427832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder.
    Ben Hamida F; el Esper I; Compagnon M; Morinière P; Fournier A
    Nephron; 1993; 63(3):258-62. PubMed ID: 8446261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: a controlled study.
    Ring T; Nielsen C; Andersen SP; Behrens JK; Sodemann B; Kornerup HJ
    Nephrol Dial Transplant; 1993; 8(4):341-6. PubMed ID: 8390009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis.
    Sechet A; Hardy P; Hottelart C; Rasombololona M; Abighanem O; Oualim Z; Brazier M; Achard JM; Pruna A; Moriniere P; Fournier A
    Artif Organs; 1998 Jul; 22(7):564-8. PubMed ID: 9684692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of alkaline calcium salts as phosphate binder in uremic patients.
    Fournier A; Morinière P; Ben Hamida F; el Esjer N; Shenovda M; Ghazali A; Bouzernidj M; Achard JM; Westeel PF
    Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis.
    Toussaint ND; Polkinghorne KR; Kerr PG; Somerville CA; Agar JW
    Hemodial Int; 2007 Apr; 11(2):217-24. PubMed ID: 17403174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of high CaCO3 supplements on serum calcium and phosphorus in patients on regular hemodialysis treatment.
    Gonella M; Calabrese G; Vagelli G; Pratesi G; Lamon S; Talarico S
    Clin Nephrol; 1985 Sep; 24(3):147-50. PubMed ID: 4042444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients.
    Sawyer N; Noonan K; Altmann P; Marsh F; Cunningham J
    Nephrol Dial Transplant; 1989; 4(2):105-9. PubMed ID: 2496350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substitution of calcium carbonate for aluminum hydroxide in patients on hemodialysis. Effects on acidosis, on parathyroid function, and on calcemia.
    Anelli A; Brancaccio D; Damasso R; Padovese P; Gallieni M; Garella S
    Nephron; 1989; 52(2):125-32. PubMed ID: 2500612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium.
    Moriniere P; el Esper N; Viron B; Judith D; Bourgeon B; Farquet C; Gheerbrant J; Chapuy M; Van Orshoven A; Pamphile R
    Kidney Int Suppl; 1993 Jun; 41():S121-4. PubMed ID: 8320904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
    Kiss D; Battegay M; Meier C; Lyrer A
    Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The requirement of low calcium dialysate in patients on continuous ambulatory peritoneal dialysis receiving calcium carbonate as a phosphate binder.
    Cheng IK; Lu HB; Chan CY; Cheng SW; Robinson JD; Tam SC; Lo WK; Cheung WC
    Clin Nephrol; 1993 Aug; 40(2):100-5. PubMed ID: 8222365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.
    Iwasaki Y; Takami H; Tani M; Yamaguchi Y; Goto H; Goto Y; Goto Y; Shigematsu T
    Ther Apher Dial; 2005 Aug; 9(4):347-51. PubMed ID: 16076380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.